David A. Siegel Anavex Life Sciences Corp. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 493,500 shares of AVXL stock, worth $4.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

493,500

Previous 633,000 22.04%

Holding current value

$4.26 Million

Previous $2.67 Million 4.94%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.11 - $7.04 $573,345 - $982,080	-139,500 Reduced 22.04%	493,500 $2.8 Million
Q2 2024 Aug 14, 2024	BUY	$3.39 - $5.02 $1.98 Million - $2.93 Million	584,500 Added 1205.15%	633,000 $2.67 Million
Q1 2024 May 15, 2024	BUY	$4.55 - $6.75 $220,675 - $327,375	48,500 New	48,500 $246,000
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $83,185 - $118,998	-12,700 Reduced 47.21%	14,200 $93,000
Q2 2023 Aug 14, 2023	SELL	$7.66 - $9.5 $1.18 Million - $1.46 Million	-153,700 Reduced 85.11%	26,900 $218,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $594,880 - $840,125	71,500 Added 65.54%	180,600 $1.55 Million
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $516,375 - $974,025	67,500 Added 162.26%	109,100 $1.01 Million
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $246,530 - $356,222	27,700 Added 199.28%	41,600 $429,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $125,001 - $219,564	-17,100 Reduced 55.16%	13,900 $139,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $301,940 - $548,390	31,000 New	31,000 $382,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account